Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Acotec Scientific Holdings Limited (6669.HK)
Beijing, CN
Acotec Scientific Holdings Limited is a medical technology firm specializing in the research and development of percutaneous transluminal angioplasty (PTA) and drug-coated balloon devices. These innovative products are designed to address various vascular diseases across Mainland China, Europe, and international markets. One key product, AcoArt Orchid & Dhalia, is developed to prevent the narrowing or blockage of superficial femoral and popliteal arteries, offering a treatment for lower extremity artery disease. This product is also currently undergoing clinical trials for additional applications, including arteriovenous fistula stenosis in nephrology, vertebral atherosclerotic stenosis in neurology, and vasculogenic erectile dysfunction in andrology. Another offering, AcoArt Tulip & Litos, is in the process of registration in China and Europe. Furthermore, it is under preclinical evaluation in the United States for treating below-the-knee artery disease within vascular surgery, and also for vasculogenic erectile dysfunction in andrology. The company was founded in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of CA Medtech Investment (Cayman) Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.11% | -1.11% | -6.32% | -28.80% | -27.99% | -34.07% | +12.94% | -43.67% | -49.43% | -49.43% | -49.43% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+20.7% ★ Q4'25: +21.4% (vs Q4'24)
-
EPS growth Medical - Devices: +28.5%+129.4% ★ Q4'25: +144.4% (vs Q4'24)
-
FCF margin FCF growth · Medical - Devices: +30.9%+10.3% Q4'25: +44.3% (vs Q4'24)
-
EBIT margin Medical - Devices: +6.2%+16.4% ★ Q4'25: +9.7% (vs Q4'24)
-
ROIC Medical - Devices: +3.3%+13.4% ★ Q4'25: +6.9% (vs Q4'24)
-
Share dilution Medical - Devices: 0.0%+0.3% Q4'25: +0.4% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.89× ★ Q4'25: 3.08× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
303.81M
est: 370.95M (-18.1%)
|
395.55M
est: 497.15M (-20.4%)
|
473.85M
est: 486.61M (-2.6%)
|
533.99M
est: 570.79M (-6.4%)
|
644.63M
est: 711.70M (-9.4%)
|
765.65M
765.65M – 765.65M
+7.6% YoY
|
1.01B
1.01B – 1.01B
+32.2% YoY
|
1.37B
1.37B – 1.37B
+35.4% YoY
|
| EBITDA |
-51.02M
est: 21.88M (-333.1%)
|
91.17M
est: 29.33M (+210.9%)
|
70.54M
est: 60.65M (+16.3%)
|
112.48M
est: 71.14M (+58.1%)
|
129.65M
est: 88.71M (+46.1%)
|
95.43M
95.43M – 95.43M
+7.6% YoY
|
126.20M
126.20M – 126.20M
+32.2% YoY
|
170.87M
170.87M – 170.87M
+35.4% YoY
|
| EBIT |
-63.42M
est: -1.03M (-6,055.9%)
|
71.73M
est: -1.38M (+5,295.6%)
|
24.29M
est: 29.69M (-18.2%)
|
62.50M
est: 34.82M (+79.5%)
|
105.81M
est: 43.42M (+143.7%)
|
46.71M
46.71M – 46.71M
+7.6% YoY
|
61.77M
61.77M – 61.77M
+32.2% YoY
|
83.64M
83.64M – 83.64M
+35.4% YoY
|
| Net Income |
-79.08M
est: -24.12M (-227.8%)
|
70.14M
est: 68.84M (+1.9%)
|
14.49M
est: 29.90M (-51.6%)
|
52.28M
est: 78.48M (-33.4%)
|
119.18M
est: 108.65M (+9.7%)
|
159.72M
159.72M – 159.72M
+47.0% YoY
|
259.93M
259.93M – 259.93M
+62.7% YoY
|
363.27M
363.27M – 363.27M
+39.8% YoY
|
| SGA |
158.02M
est: 139.09M (+13.6%)
|
160.51M
est: 186.41M (-13.9%)
|
181.32M
est: 183.60M (-1.2%)
|
157.59M
est: 215.36M (-26.8%)
|
182.33M
est: 268.53M (-32.1%)
|
288.89M
288.89M – 288.89M
+7.6% YoY
|
382.02M
382.02M – 382.02M
+32.2% YoY
|
517.25M
517.25M – 517.25M
+35.4% YoY
|
| EPS |
-0.32
est: -0.08 (-299.4%)
|
0.23
est: 0.23 (+0.6%)
|
0.05
est: 0.10 (-51.4%)
|
0.17
est: 0.26 (-34.6%)
|
0.39
est: 0.36 (+8.4%)
|
0.53
0.53 – 0.53
+47.0% YoY
|
0.86
0.86 – 0.86
+62.7% YoY
|
1.20
1.20 – 1.20
+39.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.00% | 3.2K | 0.42% |
| 2 | Avantis Emerging Markets Value ETF AVES | 0.00% | 16.0K | 0.36% |
| 3 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 1.1K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jing Li | Executive Chairperson of the Board & Chief Executive Officer | 4M | female |
| Chen Li | Joint Company Secretary | — | male |
| Ching Yi Li | Joint Company Secretary | — | female |
| Ulrich Reinhold Speck | Chief Technology Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6669.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
